Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Acrivon Therapeutics, Inc.ACRV · Entity 573 | Chief Medical Officer | May 18, 2026 | May 20, 2026 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | Director | May 28, 2025 | May 29, 2025 |
| SERA PROGNOSTICS, INC.SERA · Entity 304 | Director | July 10, 2026 | July 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Acrivon Therapeutics, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,817 |
Reported balance
After 2026-05-18 transaction · row 1
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 38,817 · Balance 38,817 F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.
Karyopharm Therapeutics Inc.
Report date May 28, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.48 · Expires 2035-05-27 | Direct | 4,600 |
Reported balance
After 2025-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-28 · Grant · Acquired 4,600 · Balance 4,600 F1: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2: This option vests as to 100% of the underlying shares on May 28, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
F2: This option vests as to 100% of the underlying shares on May 28, 2026.
SERA PROGNOSTICS, INC.
Report date July 10, 2026 · Filed July 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 81,937 |
Ending reported balance
After 2026-07-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-10 · Grant · Acquired 22,426 · Balance 80,166 F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Row 2 · 2026-07-10 · Grant · Acquired 1,771 · Balance 81,937 F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 34,494 |
Reported balance
After 2026-07-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-10 · Grant · Acquired 34,494 · Balance 34,494 F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-07-10 | Direct | 2,725 |
Reported balance
After 2026-07-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-10 · Grant · Acquired 2,725 · Balance 2,725 F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F2: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F3: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
F4: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 14, 2026 22:43 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 2,725 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001588389-26-000002 · ownership.xml · derivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,725 Underlying: Class A Common Stock · 2,725 shares Expires 2036-07-10 F4 · derivative.exercise_date: These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:43 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 34,494 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001588389-26-000002 · ownership.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,494 Underlying: Class A Common Stock · 34,494 shares Expires 2036-07-10 F3 · derivative.exercise_date: Consists of stock options granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the grant date; provided, however, that the stock options shall be fully vested on the earlier of the first anniversary of the grant date or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:43 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 1,771 | $0.00 | $0.00 |
DisclosureSEC source: 0001588389-26-000002 · ownership.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,937 F2 · shares: Each share is represented by an additional RSU granted by the Board of Directors. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| July 10, 2026 Filed Jul 14, 2026 22:43 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 22,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001588389-26-000002 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,166 F1 · shares: Each share is represented by a restricted stock unit ("RSU") granted pursuant to the issuer's Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These RSUs vest on the earlier of July 10, 2027 or the date of the issuer's next Annual Meeting of Stockholders, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| May 18, 2026 Filed May 20, 2026 20:30 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantCommon Stock | 38,817 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-002555 · form4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,817 F1 · kind: These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. Of these RSUs, 16.67% of the RSUs shall vest on November 18, 2026, and the remaining RSUs shall vest in 10 substantially equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 21:21 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 174,068 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0000905148-26-001120 · form4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,068 Underlying: Common Stock · 174,068 shares Expires 2036-02-29 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on March 1, 2027, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| December 05, 2025 Filed Dec 5, 2025 22:25 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 292 | $3.05 | $890.60 |
DisclosureSEC source: 0001193125-25-309950 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,740 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.01 to $3.08, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 05, 2025 Filed Nov 6, 2025 22:05 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 221 | $3.04 | $671.84 |
DisclosureSEC source: 0001193125-25-270062 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,032 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.03 to $3.05, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 06, 2025 Filed Oct 6, 2025 20:15 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 227 | $3.16 | $717.32 |
DisclosureSEC source: 0001193125-25-231898 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,253 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.15 to $3.20, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:28 UTC | Acrivon Therapeutics, Inc. ACRV · Entity 573 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000905148-25-003507 · form4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2035-09-30 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option vest on November 1, 2026, and the remaining shares subject to the option vest in 36 substantially equal monthly installments thereafter, in each case subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| September 05, 2025 Filed Sep 5, 2025 22:37 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 222 | $3.35 | $743.70 |
DisclosureSEC source: 0001588389-25-000008 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,480 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.35 to $3.36, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 22:07 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 225 | $2.50 | $562.50 |
DisclosureSEC source: 0000950170-25-103280 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,702 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 07, 2025 Filed Jul 8, 2025 21:08 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 234 | $2.36 | $552.24 |
DisclosureSEC source: 0000950170-25-094633 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,927 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 06, 2025 Filed Jun 6, 2025 22:39 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 107 | $1.58 | $169.06 |
DisclosureSEC source: 0000950170-25-083336 · ownership.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,161 F2 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:39 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0000950170-25-083336 · ownership.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2035-06-05 F3 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025. Read SEC document |
| June 05, 2025 Filed Jun 6, 2025 22:39 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 15,596 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083336 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,268 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 5, 2025, subject to the Reporting Person continuing to provide services to the issuer. Read SEC document |
| May 28, 2025 Filed May 29, 2025 20:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 4,600 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0000950170-25-078950 · ownership.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,600 Underlying: Common Stock · 4,600 shares Expires 2035-05-27 F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026. F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025. Read SEC document |
| May 08, 2025 Filed May 9, 2025 23:18 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 106 | $2.44 | $258.64 |
DisclosureSEC source: 0000950170-25-068394 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,672 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $2.10 to $2.78, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| April 07, 2025 Filed Apr 8, 2025 21:21 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 107 | $3.35 | $358.45 |
DisclosureSEC source: 0000950170-25-052193 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,778 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| March 06, 2025 Filed Mar 8, 2025 00:30 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 99 | $4.16 | $411.84 |
DisclosureSEC source: 0000950170-25-035804 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,885 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.07 to $4.24, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:13 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 101 | $4.58 | $462.58 |
DisclosureSEC source: 0000950170-25-021199 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,984 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $4.14 to $5.09, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| January 27, 2025 Filed Jan 27, 2025 23:33 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionStock Option (right to buy) · Derivative | 37,549 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000950170-25-009338 · ownership.xml · derivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 37,549 shares Expires 2025-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are fully vested and exercisable. Read SEC document |
| January 27, 2025 Filed Jan 27, 2025 23:33 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | Exercise / conversionClass A Common Stock | 37,549 | $0.91 | $34,169.59 |
DisclosureSEC source: 0000950170-25-009338 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,085 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 21:05 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 100 | $7.69 | $769.00 |
DisclosureSEC source: 0000950170-25-002823 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,536 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| December 06, 2024 Filed Dec 9, 2024 21:52 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 93 | $7.12 | $662.16 |
DisclosureSEC source: 0000950170-24-134615 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,636 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| November 11, 2024 Filed Nov 12, 2024 22:05 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 95 | $7.32 | $695.40 |
DisclosureSEC source: 0000950170-24-125652 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,729 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $6.30 to $8.74, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| October 07, 2024 Filed Oct 7, 2024 22:22 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 96 | $7.15 | $686.40 |
DisclosureSEC source: 0000950170-24-113343 · ownership.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,824 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| September 06, 2024 Filed Sep 9, 2024 20:46 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 96 | $7.16 | $687.36 |
DisclosureSEC source: 0001534969-24-000182 · wk-form4_1725914765.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,920 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.15 to $7.16, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:50 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | SaleClass A Common Stock | 101 | $7.42 | $749.42 |
DisclosureSEC source: 0001534969-24-000162 · wk-form4_1723150212.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,016 F1 · kind: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by "sell to cover" transactions and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price reported is a weighted average price. These shares were sold as part of a block trade in multiple transactions at prices ranging from $6.94 to $7.58, inclusive. The Reporting Person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price with regard to the block trade. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:31 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 10,549 | $0.00 Strike: $8.43 | $0.00 |
DisclosureSEC source: 0001534969-24-000132 · wk-form4_1717792300.xml · derivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,549 Underlying: Class A Common Stock · 10,549 shares Expires 2034-06-06 F2 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:31 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantClass A Common Stock | 7,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001534969-24-000132 · wk-form4_1717792300.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,117 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). These RSUs vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 6, 2024, subject to the reporting person continuing to provide services to the issuer. Read SEC document |
| May 29, 2024 Filed May 30, 2024 21:32 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 69,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000950170-24-066782 · ownership.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2034-05-28 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 29, 2025. Read SEC document |
| June 08, 2023 Filed Jul 7, 2023 20:21 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 63,265 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001534969-23-000075 · wk-form4_1688761270.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,265 Underlying: Class A Common Stock · 63,265 shares Expires 2033-06-08 F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 8, 2023. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:08 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 34,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-032144 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-05-23 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 24, 2024. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 20:58 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 149,675 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001534969-22-000086 · wf-form4_165454908463160.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,675 Underlying: Class A Common Stock · 149,675 shares Expires 2032-06-03 F1 · derivative.exercise_date: Consists of stock options granted pursuant to Sera Prognostics, Inc.'s Non-Employee Director Compensation Policy and its 2021 Equity Incentive Plan. These stock options vest over one year as follows: 1/12 of the original grant amount vests in monthly installments for one year following the vesting commencement date, which is June 3, 2022. Read SEC document |
| May 19, 2022 Filed May 20, 2022 20:07 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $5.65 | $0.00 |
DisclosureSEC source: 0001209191-22-030972 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2032-05-18 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 19, 2023 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. Read SEC document |
| May 21, 2021 Filed May 21, 2021 21:34 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 23,900 | $0.00 Strike: $9.42 | $0.00 |
DisclosureSEC source: 0001209191-21-035027 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,900 Underlying: Common Stock · 23,900 shares Expires 2031-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on the earlier of May 21, 2022 or the next annual meeting of stockholders of Karyopharm Therapeutics Inc. (the "Issuer"), provided that the reporting person continues to serve as a director of the Issuer through such date. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-20-064905 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 6, 2020. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $18.00 | $90,000.00 |
DisclosureSEC source: 0001209191-20-064905 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:16 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $5.43 | $27,150.00 |
DisclosureSEC source: 0001209191-20-064905 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.43 | $0.00 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · derivative · entry 6 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 20,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 6, 2020. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $16.14 | $80,703.50 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 5 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.00 to $16.47, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $16.04 | $80,222.50 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 4 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $16.05 | $80,226.50 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $16.05 | $80,230.50 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $15.79 to $16.46, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 07, 2020 Filed Dec 8, 2020 22:14 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 20,000 | $5.43 | $108,600.00 |
DisclosureSEC source: 0001209191-20-062319 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 21, 2020 Filed May 26, 2020 20:22 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 16,400 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0001209191-20-032009 · doc4.xml · derivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,400 Underlying: Common Stock · 16,400 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 21, 2021, provided that the reporting person continues to serve as a director of the issuer through such date. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:51 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $8.06 | $0.00 |
DisclosureSEC source: 0001209191-20-016347 · doc4.xml · derivative · entry 3 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: This option, representing a right to purchase a specified number of shares, vested as to 100% of the underlying shares on June 16, 2017. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:51 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 5,000 | $23.50 | $117,500.00 |
DisclosureSEC source: 0001209191-20-016347 · doc4.xml · nonDerivative · entry 2 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 23:51 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 5,000 | $8.06 | $40,300.00 |
DisclosureSEC source: 0001209191-20-016347 · doc4.xml · nonDerivative · entry 1 Mirza Mansoor Raza · CIK 0001588389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.